» Articles » PMID: 17371966

Four Functionally Distinct Populations of Human Effector-memory CD8+ T Lymphocytes

Overview
Journal J Immunol
Date 2007 Mar 21
PMID 17371966
Citations 196
Authors
Affiliations
Soon will be listed here.
Abstract

In humans, the pathways of memory and effector T cell differentiation remain poorly defined. We have dissected the functional properties of ex vivo effector-memory (EM) CD45RA-CCR7- T lymphocytes present within the circulating CD8+ T cell pool of healthy individuals. Our studies show that EM T cells are heterogeneous and are subdivided based on differential CD27 and CD28 expression into four subsets. EM(1) (CD27+CD28+) and EM(4) (CD27-CD28+) T cells express low levels of effector mediators such as granzyme B and perforin and high levels of CD127/IL-7Ralpha. EM(1) cells also have a relatively short replicative history and display strong ex vivo telomerase activity. Therefore, these cells are closely related to central-memory (CD45RA-CCR7+) cells. In contrast, EM(2) (CD27+CD28-) and EM(3) (CD27-CD28-) cells express mediators characteristic of effector cells, whereby EM(3) cells display stronger ex vivo cytolytic activity and have experienced larger numbers of cell divisions, thus resembling differentiated effector (CD45RA+CCR7-) cells. These data indicate that progressive up-regulation of cytolytic activity and stepwise loss of CCR7, CD28, and CD27 both characterize CD8+ T cell differentiation. Finally, memory CD8+ T cells not only include central-memory cells but also EM(1) cells, which differ in CCR7 expression and may therefore confer memory functions in lymphoid and peripheral tissues, respectively.

Citing Articles

Peripheral Immune Profiles in Individuals at Genetic Risk of Amyotrophic Lateral Sclerosis and Alzheimer's Disease.

Deecke L, Ohlei O, Goldeck D, Homann J, Toepfer S, Demuth I Cells. 2025; 14(4).

PMID: 39996723 PMC: 11852917. DOI: 10.3390/cells14040250.


CD57 EMRA CD8 T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy.

Gonnin C, Leemans M, Canoui-Poitrine F, Lebraud M, Corneau A, Roquebert L Immun Ageing. 2024; 21(1):89.

PMID: 39731117 PMC: 11673364. DOI: 10.1186/s12979-024-00487-4.


Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K Vaccines (Basel). 2024; 12(11).

PMID: 39591152 PMC: 11598869. DOI: 10.3390/vaccines12111249.


The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.

Noviello M, De Lorenzo R, Chimienti R, Maugeri N, De Lalla C, Siracusano G Front Immunol. 2024; 15:1381091.

PMID: 39136010 PMC: 11317765. DOI: 10.3389/fimmu.2024.1381091.


Stem-like T cells are associated with the pathogenesis of ulcerative colitis in humans.

Li Y, Ramirez-Suastegui C, Harris R, Castaneda-Castro F, Ascui G, Perez-Jeldres T Nat Immunol. 2024; 25(7):1231-1244.

PMID: 38898157 PMC: 11800318. DOI: 10.1038/s41590-024-01860-7.